Notch is out — your watchlist beside the MacBook notch, synced with this account.
Learn more ↗We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
명예회장 차석용의 자기 주식 변동 (+15,643주)
EPS 3,931 · 매출 1379억. 세부 수치와 가이던스는 원문에서 확인하세요.
이사 김상겸의 자기 주식 변동 (+73주)
아프로디테애퀴지션홀딩스엘엘씨의 대량보유 변동 보고
Consensus vs. actual, and revenue trend
Rating & price-target changes
Hugel is a biopharmaceutical company specializing in the development, manufacturing, and sale of botulinum toxin formulations and hyaluronic acid fillers. The company also operates businesses in medical devices and cosmetics, offering products for aesthetic and plastic surgery applications, and supplies them to both domestic and international markets.
Korean business-press RSS, supplemented with portal search and English Yahoo Finance headlines.
DJ and producer Hugel on new album, 'Twenty One'
Hugel brings WELLAGE to Sephora US with OLIVE YOUNG, strengthening global skincare growth
Hugel reports record first-half earnings driven by strong botulinum toxin growth
Hugel Aesthetics Expands U.S. Presence with Commercial, Medical and Scientific Investments
Hugel showcases global K-aesthetics momentum at AMWC KOREA
"대만 의료진과 교류"… 휴젤 , 학술 프로그램 진행
휴젤 이 대만 의료진들을 초청해 글로벌 학술 프로그램을 진행했다. 24일 휴젤 에 따르면 회사는 지난 16일부터 나흘간 대만 의료진을 국내에 초청해 글로벌 학술 프로그램 'L.E.A.D.: Letybo Experience & Discovery'를 진행했다....
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| FY2026 Q2 | 2026. 08. 14. | Time TBD | — | ₩3,931 | — | — | ₩137.9B | Reported |
| FY2026 Q1 | 2026. 05. 15. | Time TBD | — | ₩3,567 | — | — | ₩116.64B | Reported |
| FY2025 Q4 | 2026. 03. 20. | Time TBD | — | ₩3,634 | — | — | ₩119.13B | Reported |
| FY2025 Q3 | 2025. 11. 14. | Time TBD | — | ₩3,269 | — | — | ₩105.9B | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 08. 10. | 교보증권 | — | Maintain | — → — | — | 2Q26 Review; 하반기 숫자 확인 필요 |
| 2026. 08. 07. | 키움증권 | — | Maintain | — → — | — | 깔끔하잖아 숫자로도 기술적으로도 |
| 2026. 08. 07. | IBK투자증권 | — | Maintain | — → — | — | 중국으로 확인한 체력, 미국으로 여는 성장 |
| 2026. 08. 07. | 대신증권 | — | Maintain | — → — | — | 중국이 2분기 캐리 |
| 2026. 08. 07. | 미래에셋증권 | — | Maintain | — → — | — | 2Q26 Review: 우려를 낮춘 견조한 실적 |
| 2026. 07. 08. | 교보증권 | — | Maintain | — → — | — | 2Q26 Preview; 외형 성장 확대 중 |
As of FY2026Q2 · Source: SEC/DART + price data
Auto-aggregated from recent research reports (per-report average)
